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ABSTRACT 
In radiotherapy (RT), the aim is to kill all malignant cells in a tumor or to render them incapable 
of further division and multiplication without producing damage to the normal tissues 
surrounding the tumor. To achieve this, both the spatial and temporal distribution of dose 
delivery are important for optimizing the treatment. A sufficiently high dose must be delivered 
to the tumor cells and as low a dose as possible to normal tissues. The number of fractional 
doses delivered also impacts outcome due to the time-dependent repair of sublethal radiation 
damage, which differs in tumor and normal cells. In patients undergoing RT for tumors located 
in and near the thorax, irradiation of the healthy lung may induce radiation pneumonitis (RP), 
which can be a serious problem. Understanding the factors involved in the onset of RP is 
important for reducing its incidence  
The overall aim of the thesis was to determine if radiation-induced side effects in lung can be 
modelled in terms of the spatial and temporal distributions of the doses delivered in 
conventional RT for breast cancer (BC) and hypofractionated stereotactic body radiotherapy 
(SBRT) for lung cancer. 
Radiological changes in the lung were quantified with Computer Tomography (CT) after RT in 
121 patients with breast cancer (BC). Their association with the spatial dose distribution as well 
as incidence of RP where studied. It was found that RP and radiological findings were 
associated with the spatial dose distribution. In a subgroup of 87 patients, data of the spatial 
dose distribution and incidence of RP were modelled using four different normal tissue 
complication probability (NTCP) models. The studied models fit quite accurately to data for the 
considered endpoints.  Mean lung dose was shown to be a robust and simple parameter that 
correlated with the risk of RP. 
The calculated spatial dose distribution in SBRT of tumors in the lungs, including breathing 
motions, were assessed for accuracy. The analysis showed that the dose in the central part of the 
gross tumor volume (GTV) was accurate to within 2–3% for commonly used algorithms; 
however in the lung tissue close to the GTV the different algorithms both over- and 
underestimates it, depending on type. When clinically relevant breathing motions were 
considered, the dose calculated for a static situation remained a relatively accurate estimate of 
the dose in the GTV.  Data of dose distributions and incidence of RP after SBRT for lung 
cancer were fitted to a NTCP model in a cohort of 57 patients. Correction for fractionation was 
done in two ways: with the Linear-Quadratic (LQ) model and the Universal Survival Curve 
(USC). The modelling showed that low dose volumes contributes less to NTCP and high dose 
volumes comparatively more with the USC model, than the LQ model. The impact of 
fractionation in SBRT was analyzed using the LQ- and USC models for fractionation 
correction. The therapeutic window was shown to increase with number of fractions for a range 
of regimes (2 to 20 fractions) at target doses common in SBRT. Generally, a larger gain was 
predicted with the USC correction. At high doses per fraction, typical in SBRT, the USC model 
predicted a lower sensitivity for fractionation as compared to the LQ model.  
In conclusion, the incidence of RP can be modelled, accounting for spatial and temporal dose 
distributions, especially in conventional RT of BC. In SBRT, with a more focused irradiation to 
very high doses, some uncertainties remain, both regarding the dependence of the spatial dose 
distribution and particularly of fractionation. The modelling shows that a less extreme hypo 
fractionation in SBRT may be a way to increase indications for SBRT. Generally, more data is 
needed for improved modelling. 
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1 INTRODUCTION 
The aim of radiotherapy1 (RT) is to kill all the malignant cells2 in a tumor or to 
render them incapable of further cell division and multiplication without damage to 
the normal tissues surrounding the tumor. Owing to the way radiation interacts 
with matter, avoiding some radiation-induced cell-killing in normal tissue is 
impossible.  However, the differences in radio sensitivity between normal cells and 
tumor cells, together with minimizing dose to normal tissues facilitates RT without 
causing excessive damage1.  
 
In optimizing RT, the following needs to be considered. The accurate 
determination of the volume in the body that should be treated (containing 
malignant cells), the accurate determination of the volumes of normal tissues, to 
which the doses must be restricted in order to avoid side effects3, the dose that 
needs to be delivered to the tumor volume as well as the dose restrictions to the 
normal tissues must be defined. The sequential pattern of dose delivery must also 
be determined for optimal utilization of the time-dependant repair of radiation 
damage, which differs in normal cells and tumor cells. 
 
Thus, important considerations for an optimized RT are: 
x The spatial distribution of the dose delivery with a sufficiently high dose 
to the tumor cells and sufficiently low dose to normal tissues.  
x The temporal distribution of the dose delivery to minimize the repair of 
radiation damage in tumor cells and maximize it in normal cells.
 
 
1.1 RESPONSE TO RADIATION IN CELLS 
Cells die naturally after maturation followed by senescence. The life time of 
functional cells varies enormously. The fate of the cells also varies with type of 
tissue. However, after cytotoxic injury, two types of cell death occurs - interphase 
death or mitotic death. The latter is the most common and important form of cell 
death induced by radiation. Since cell death is defined as loss of reproducing 
capacity (mitotic death) a non-viable damaged cell might appear to be intact even 
while a locally controlled tumor still is present4. When normal tissue is damaged 
by radiation its regeneration depends on the number of stem cells5 that have 
survived and on the integrity of their capacity for proliferation.  
An approach to understanding the effect of radiation on tissue involves identifying 
the target cells and their depletion, effecting tissue function. During the last 
decades, new insights regarding cells and the cell cycle have increased 
understanding about how tissues respond to radiation. We know that radiation 
sensitivity depends of cell type and on their degree of cellular differentiation. Stem 
cells are the most radiosensitive and fully differentiated cells, which no longer 
divide, are very radio resistant. The appearance and repair of damage may have 
different time courses depending on how the tissue are organised. As different 
tissues have different radio sensitivity and different response to radiation injury 
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different approaches to RT have to be taken depending on surrounding tissues of 
the tumor6.  
After irradiation with a very large dose, of several hundred Gray (Gy), all cell 
function ceases and cell death is immediate. With lower doses of a few Gy to cells 
that are dividing or that are still able to divide, only a proportion of cells lose their 
capacity for division or proliferation4.  
The death of clonogenic cells irradiated in-vitro versus the dose given is generally 
described by an exponential function, i.e. a linear decrease of surviving cells with 
dose, plotted on a log-linear scale. Accordingly, the clinical experience from RT of 
macroscopic tumors with a large number of cells is that they require a much higher 
dose for ablation than microscopic tumors.  
 
The biological factors that influence the response of normal and tumor tissue are 
summarised by the four Rs of radiotherapy, so-christened by Withers, 1975 7. 
Repair – as seen by cellular recovery during few hours after exposure. 
Reassortment – cell cycle progression effect. Cells that survive a first dose of 
radiation may be in a resistant phase of the cell cycle and then progress into a more 
radiosensitive phase within a few hours. 
Repopulation – during a 4- to 6 week course of RT, tumor cells that survive may 
proliferate and increase the number of cells that must be killed. 
Reoxygenation – in a tumor the resistant hypoxic cells will selectively survive after 
a dose fraction, but thereafter their oxygen supply increases and their 
radiosensivity will increase. 
Two of these processes will tend to make the tissue more resistant (repair and 
repopulation) and two more sensitive and as a consequence lately a fifth R has 
appeared: 
Radiosensensitivity- some tumors have a different response to radiation even if 
allowing for different timing of responses and this is largely due to differences in 
radiosensitivity. 
 
Models that describe radiation-induced cell kill versus dose are presented below in 
Chapter 3, Fractionation effect models. 
 
 
 
1.2 DOSE-RESPONSE CURVES IN TISSUES 
The death or damage of cells due to radiation may result in clinical effects, in 
normal tissues - side effects. Existing descriptions of the mechanisms from cell 
kill/damage of different cells within an organ, to the final clinical observation of a 
side effect are largely incomplete8. 
Dose-response curves, i.e. the probability of an observed side effect versus dose, 
are determined from clinical data of incidence and given dose. A general 
assumption is that the side effect observed in an organ is directly related to the 
dose delivered to that organ. This may in some cases not be a complete description, 
and radiation damage in the vicinity of the organ may be part of the genesis of the 
observed effect.   
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1.3 BREAST AND LUNG CANCER 
Cancer Incidence 
During 2009 there were 54 611 cases of malignant cancers diagnosed and reported 
to the Swedish Cancer Registry; 53 percent of them in men and 47 per cent in 
women. The last two decades the average annual increase in number of cases has 
been 1.9 per cent for men and 1.3 per cent for women. The increase is partly 
explained by the ageing population but also by the introduction of screening 
activities and improvements in diagnostic practices11.  
 
Carcinoma of the Breast 
Breast cancer (BC) is the most common malignant tumor in Swedish women 
representing 29 percent of the female cases in 2009 and today 7000 new cases are 
diagnosed per year. BC starts in the tissues of the breast and may be invasive, that 
is spreads from the milk duct or lobule to other tissues in the breast or noninvasive 
and retain locally in situ. 
The treatment for breast carcinoma depends mainly on the tumor’s clinical stage 
when the patient is first seen – surgery and radiotherapy have essential roles as 
well as hormonal therapies12-14. RT is mostly given postoperatively to the afflicted 
breast or remaining chestwall and depending on tumor stage also to the ipsilateral 
supraclavicullar, axillary and internal mammary lymph glands (loco-regional). 
Reactions to RT occur early as well as late but are not often severe. The most 
common potential late sequelae of RT are chronic changes of the irradiated skin 
and soft tissue (fibrosis, hyperpigmentation and rarely telangectasias). In patients 
who undergo axillary node dissection and receive adjuvant irradiation to the axilla, 
the risk of lymphoedema significantly increases with the addition of radiation. The 
risk of complications in the joints, ribs (fractures), and brachial plexus is relatively 
low with current treatment techniques 
 However, RT for breast cancer has also, until recently, been associated with an 
increased risk of developing ischaemic heart disease15. Furthermore side-effects to 
the lungs can take the form of acute pneumonitis and sub acute/late lung fibrosis 
which for some patients can adversely affect the quality of life. When RT is given 
as an adjuvant treatment and in combination with other treatments such as surgery, 
hormonal therapy and chemotherapy it is important to minimize RT induced side 
effects.  
 
Tumors of bronchus and lung 
Of all the cancer cases recorded in Sweden during 2009, lung cancer represents 6.3 
percent for males and 7 percent for women.  Lung cancer is the most common 
cause of cancer-related deaths in both men and women throughout the world. Lung 
cancers can arise in any part of the lung, but 90%-95% of cancers of the lung are 
thought to arise from the epithelial cells, the cells lining the larger and smaller 
airways (bronchi and bronchioles). Lung cancer tends to spread or metastasize very 
early after it forms. The lung is also a very common site for metastasis from 
tumors in other parts of the body.  
Pulmonary cancers are broadly classified into two types: small cell lung cancers 
(SCLC) and non-small cell lung cancers (NSCLC).  SCLC comprises about 20% 
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of all lung cancers and is the most aggressive and rapidly growing of all lung 
cancers. NSCLC is the most common lung cancer, accounting for about 80% of all 
lung cancers.  
Treatment for lung cancer can involve surgical removal of the cancer, 
chemotherapy, or RT, as well as combinations thereof16-18. The treatment of choice 
has been radical surgery but only subset of lung cancer patients are suitable 
candidates for surgery. Common early reactions to RT are lung reactions which 
range between early transient pneumonitis to more serious late occurring fibrosis, 
skin reaction and fatigue. For more centrally located lung tumors severe reactions 
may occur within the esophagus19. 
 
 
1.4 ORGANS AT RISK AND DOSE VOLUME CONSTRAINTS 
Normal tissues surrounding a tumor may be a dose-limiting consideration in RT by 
virtue of their near proximity to the target volume (e.g., rectum near the prostate, 
heart near the left breast, parotids near head and neck tumors) or the tumor’s whole 
or partially localization within a functioning organ (e.g., primary or metastatic 
tumors or malformations in the liver, lung and brain).  
The International Commission on Radiation Units and Measurements (ICRU) 
provides guidelines for working with radiation. In report 5020, volumes that must 
be identified prior to any RT are defined: the gross tumor volume (GTV), the 
clinical target volume (CTV) and the planning target volume (PTV). Organs at risk 
(OAR) are defined as normal tissue whose radiation sensitivity may significantly 
influence treatment planning and/or prescribed dose. Thus a healthy organ may or 
may not be defined as an OAR, depending on the dose to the organ and volume of 
the organ to be irradiated.  
Dose/volume constraints are available in the litterateur and lists doses that, given to 
a certain volume fraction of an organ, will cause a specified side effect at a certain 
level of probability. The latest overview and summary of recommended 
dose/volume constraints are published by QUANTEC (Quantitative Analysis of 
Normal Tissue Effects in the Clinic)21. The accuracy of dose-response data is 
limited, as discussed in the QUANTEC report and also below.   
 
 
1.5 RADIATION INDUCED SIDE-EFFECTS IN LUNG 
The principal function of the lungs is to exchange gases between the air we breathe 
and the blood. The right lung has three lobes, whereas the left lung is divided into 
two lobes and a small structure called the lingual that is the equivalent of the 
middle lobe on the right side. The major airways entering the lungs are the bronchi, 
which arise from the trachea. The bronchi branch into progressively smaller 
airways called bronchioles that end in tiny sacs known as alveoli, where gas 
exchange occurs. The lungs and chest wall are covered with a thin layer of tissue 
called the pleura. 
Radiation induced lung injury has two waves of damage. Radiation pneumonitis 
(RP) occurs after 3 to 6 months and is characterized by interstitial oedema and 
oedema in airspaces affecting the patient with dry cough, dyspnea and fever. These 
lesions may be reversible. A later wave of injury occurs after 9 months presumably 
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results from lung fibrosis. These injuries may increase in severity for up to 1 – 2 
years before stabilizing. RT-induced pulmonary complications such as 
pneumonitis result from injury to type II pneumocytes, and endothelial cells, 
become manifest after an initial latent period reflecting the inherent turnover time 
of the affected cells22. Late injury from RT appears clinically and histologically as 
progressive fibrosis, but the mechanism is not completely clear23. 
To diagnose radiation-induced lung injury many different end-points can be used 
22, 24 : 
 
x Radiographic. Appears within a few months after RT, increases in tissue 
density associated with acute inflammation or late fibrosis typically seen 
on either chest x-rays (CXR) or computed tomography (CT). The latter is 
more sensitive because it provides better 3-dimensional (3D) visualization 
of the lung 25-27. 
x Clinical. Acute pneumonitis typically presents 1 to 6 months after RT, 
with symptoms of shortness of breath, cough and occasionally mild fever. 
Pneumonitis usually responds well to steroids22. 
x Late. Clinically significant RT-induced fibrosis is typically described as 
progressive chronic dyspnea associated with scarring of the irradiated 
lung, typically occurring months to years after RT22, 23. 
x Functional Endpoints.The primary function of the lungs is to provide 
oxygen to, and extract carbon dioxide from, the pulmonary circulation. 
Spirometry assesses the rate of gas movement; the most commonly 
measured parameter is the forced expiratory volume in one second 
(FEV1) 28. 
Although the ultimate endpoint of “incidence of pulmonary toxicity” differs 
significantly based on the method used to quantify pulmonary complications, 
whether it be assessment of patient symptoms, chest radiographs, pulmonary 
function testing, perfusion studies, or CT scans, studies have suggested that the 
frequency of pulmonary toxicity can be predicted29, 30, but RP is a clinically 
diagnosed factor and, as such, prone to be observer dependent31. Work has been 
done to diagnose RP by objective means with different clinical (lung physiology) 
and radiological parameters (CT-scan), but correlations to clinically relevant side 
effects have not yet been established. 
 
Reporting toxicity 
As the response of the lungs to radiation is a continuous effect with no clear steps, 
clear cut definitions of how to score such reaction have to be agreed upon.  The 
National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2 scale is 
based on symptoms only (Table 1) 32.  
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Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
No 
increase in 
pulmonary 
symptoms due to 
irradiation 
Increase in 
pulmonary 
symptoms not 
requiring initiation 
or increase 
in steroids and/or 
oxygen 
RT-induced 
pulmonary 
symptoms 
requiring 
initiation or 
increase in 
steroids 
RT-induced 
pulmonary 
symptoms 
requiring 
oxygen 
RT-induced 
pulmonary 
symptoms requiring 
intubation or 
causing death. 
 
 
Table 1. The modified National Cancer Institute Common Toxicity Criteria (NCI-CTC) 
issued by The U.S National Institutes of Health 
 
The Radiation Therapy Oncology Group/European Organization for Research and 
Treatment of Cancer (RTOG/EORTC) scoring schema has had extensive use in 
EORTC and RTOG studies and has been used by other groups as well. This 
protocol combines clinical symptoms and radiological changes (Table 2) and deals 
separately with acute and late reactions 33. 
 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
ACUTE/    
No 
change  
Mild 
symptoms of 
dry cough or 
dyspnea on 
exertion  
 Persistent cough   
requiring narcotic 
antitussive agents/ 
dyspnea with 
minimal effort but 
not at rest  
Severe cough 
unresponsive to 
narcotic antitussive 
agent or dyspnea at 
rest/ clinical or 
radiologic evidence of 
acute pneumonitis/ 
intermittent oxygen or 
steroids may be 
required  
Severe 
respiratory 
insufficiency/ 
continuous 
oxygen or 
assisted 
ventilation   
LATE/     
None Asymptomatic 
or mild 
symptoms 
(dry cough) 
Slight 
radiographic 
appearances 
Moderate 
symptomatic 
fibrosis or 
pneumonitis 
(severe cough) 
Low grade fever  
Patchy 
radiographic 
appearances 
Severe symptomatic 
fibrosis or pneumonitis 
Dense radiographic 
changes  
Severe 
respiratory 
insufficiency/ 
continuous O2/ 
Assisted 
ventilation  
 
Table 2. RTOG/EORTC Acute and Late Radiation Morbidity Scoring Criteria for Lungs 
 
Clinical data using these two different scales have been compared as though they 
give similar results34. The conclusion was that the assessment of radiation-induced 
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lung toxicity differs depending on the scoring system used. Therefore, caution 
should be used in comparing results from reports that rely on different scoring 
scales. A scale based on symptoms only, such as the NCI-CTC scale, may be more 
appropriate for evaluating long-term toxicity after curative radiotherapy for lung 
cancer.  In presented papers, the NCI-CTC scale is used, with both RP grade 1 and 
grade 2 (marked) or higher used as end-points. 
However, the spectrum of confounding variables can have an impact on normal 
tissue tolerance. Examples of confounding variables include the use of concurrent 
chemotherapy, radiation protectors or other biological modifiers, and the interval 
between radiation courses in patients undergoing a second course of RT. Other 
related variables include co-morbid conditions (e.g., diabetes and collagen vascular 
disease), patient  age, regional variation of radiosensitivity within an organ, and 
hierarchal organization of the organ (i.e., whether damage to a portion of the organ 
affects only that portion or has more widespread effect). Furthermore, an organ 
may have more than one type of late toxicity that may or may not have different 
tolerance doses.  
 
 
 
1.6 RT FOR BREAST CANCER WITH CONVENTIONAL 
FRACTIONATION 
RT for BC with a curative intent is generally given to halt possible microscopic 
spread of the tumor in local – (the breast) or loco-regional (breast + regional lymph 
nodes) volumes after surgical resection of the primary macroscopic tumor. 
Consequently, the prescribed dose is relatively moderate, on the order of 50 Gy, 
usually given with 2 Gy per fraction. The factors most closely associated with 
radiation-induced pulmonary complications of breast cancer treatments are total 
radiation dose, irradiated lung volume and fractionation schedule. Other factors 
that also impact the induction of RP are chemotherapy12 anti-hormonal therapy35, 
smoking habits36 age  and lung physiology37. 
 
The treatment is generally given with a standardized technique and may differ 
among hospitals, depending on the equipment available. Photon beams of 6 to 15 
MV and in some situations electron beams are used. Organs at risk requiring 
consideration are primarily lungs and on patients with left sided tumor locations 
also the heart. Although modern-day techniques have significantly reduced the risk 
of lung and cardiac complications, careful 3-D treatment planning should be used 
to minimize the radiation doses to these relatively sensitive organs38. The dose to 
the lungs are either high and confined to a relatively small volume fraction as 
shown in the upper panel in Figure 2, or more smeared out in a higher volume 
fraction as illustrated in the lower panel. 
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Comparison of typical lung doses are shown in Figure 4 of conventional 
fractionated radiotherapy (CFRT) of tumors in the lungs/breast to that of SBRT of 
tumors in the lungs. The figure shows dose-volume histograms for the lung volume 
with a relatively large span in spatial dose distribution. Even more pronounced is 
the span in temporal distribution of the dose delivery with typically 5 to 6 weeks 
for CFRT as compared to one week for SBRT. An even more extreme case with 
regard to dose distribution to the lung is the graph representing whole lung 
irradiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Representative DVHs for different types of thoracic treatments. Loco-regional 
BC and lung cancer with CFRT, whole lung irradiation with CFRT and of lung lesions 
with hypofractionated  SBRT. 
 
 
 
In Figure 5, data of the incidence of radiation induced pneumonitis of grade 2 or 
more (RP2+) is plotted versus mean lung dose (MLD) (from Paper IV).  Looking 
at Figure 5, one is tempted to conclude that MLD is a predictor of lung toxicity 
separately for RT of the whole lung and for partial lung irradiations such as RT in 
BC and LC, with different dose-response curves. According to historical data, a 
MLD of 18 Gy in whole lung irradiation was associated with no toxicity but with 
conventional treatment techniques (lung cancer and BC) of limited volumes of the 
lung, the same MLD was instead associated with significant toxicity, up to 
15percent (Figure 5). Thus, for the same MLD, the response of the lung depends 
on the dose-volume characteristic of the irradiation. This observation highlights the 
question; does a high dose of focused irradiation, as in SBRT, give a different 
response in the lung compared to that from CFRT? An answer could be that 
separate volumes of the lungs have different radiosensitivities 48. 
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Figure 5. Incidence of RP2+ as a function of MLD in patients irradiated in the thoracic 
region. The dashed line is a fit to the data for whole lung irradiation and the solid line a fit 
to the data for CFRT of breast– and lung cancer. 
 
The mechanisms of radiation induced lung toxicity are likely to be too complex for 
a “global” model useful for predicting lung toxicity for all possible techniques used 
in the clinic.  
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2 AIM OF THE THESIS  
The overall aim of this thesis is to investigate how radiation induced side effects 
correlates with and can be modelled in terms of the spatial and temporal 
distributions of the dose delivery in conventional RT for BC and SBRT of lung 
cancer. 
 
The specific aims of these studies were: 
 
x To quantify radiological changes in the lung with CT after RT for BC and 
to establish their association with the spatial dose distribution of RT and 
symptomatic RP. (Paper I) 
 
x To fit data of the spatial dose distribution to the incidence of short-term 
pulmonary complications in patients treated for BC, using four different 
NTCP-models. (Paper II) 
 
x To investigate the accuracy of the calculated spatial dose distribution in 
SBRT of tumors in the lungs, including breathing motions. (Paper III) 
 
x To fit data of the spatial and temporal dose distributions to incidence of 
pulmonary complications in patients treated with SBRT for lung cancer, 
using two different models for fractionation correction. (Paper IV) 
 
x To analyze the impact on the probability of pulmonary complications using 
two different models for fractionation correction in SBRT of tumors in the 
lungs and study how the therapeutic window is affected by fractionation for 
a range of regimes of 2 to 20 fractions at target doses common in SBRT. 
(Paper V) 
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Figure 6. Two important aspects of fractionation demonstrated here are, first, that 
the therapeutic window can be increased, and second, that a considerably higher 
dose must be delivered for the same cell kill with fractionation as compared to that 
with a single dose.  
There are two interpretations of cell survival curves with shoulders. 
1. Cell death occurs from an accumulation of events that are individually incapable 
of killing the cell but together becomes lethal (target model). 
 2. Lesions are individually reparable but become irreparable and kill cells if the 
repair mechanism diminish with the number of lesions i.e. dose (repair models). 
 
 
3.1 EQUIVALENT BIOLOGICAL EFFECT MODELS 
Cell survival models can be used to calculate iso-effective doses in fractionated RT 
assuming complete- or incomplete repair between fractions. To be useful in 
clinical practice the parameters of the models must be determined from in vivo 
data. In the following sections some of the target models are described in more 
detail. 
 
3.2 THE SINGLE HIT MULTI TARGET (SHMT) 
The cell is considered to contain     distinct and identical targets that are 
individually affected by radiation.  Cell kill occurs when all targets have been 
inactivated. The surviving fraction of cells after a dose d can be described as: 
 
 
    (1) 
 
where D0  and      respectively describe the slope and the extrapolation number of 
the linear part in a plot of the logarithm of survival versus dose. This relationship is 
based on the hypothesis that damage to the target is random and the probability of 
a target being undamaged is an exponential function of the dose, exp(-d/D0)50. This 
model has mainly been used to fit to in vitro data. 
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3.3 THE LINEAR-QUADRATIC (LQ) MODEL 
According to this model a cell can be killed in two ways, either by a single-track 
event or by two-track events and approximates clonogenic survival data with a 
linear quadratic (LQ) formula9 where the survival S after a dose of d is given by: 
 
  (2) 
 
 
The parameters Į and E describes, respectively, the initial slope and the “bending” 
of the curve in a log-linear plot. After n fractions with a dose of d per fraction the 
survival S is given by: 
 
ndd
LQ eS )(
))(( 2ED    (3)  
 
Denoting log of cell kill as the effect of the irradiation E, that is E = -ln (SLQ), 
equation 3 above can be written: 
 
)
/
1( EDD
dndE     (4) 
 
Fowler suggested that E/Dbe called the Biologically Effective Dose (BED), which 
can be described by a single parameter DE The significance of the DE ratio was 
explained from data collected in fractionation studies in mice52. In a log-log plot of 
iso-effective total dose versus dose per fraction plotted from right to left, there was 
a systematic tendency that late-responding tissues had steeper iso-effect lines than 
the early-responding tissues. Thus the sensitivity for fractionation was higher for 
late responding tissues. Modelling the data with the LQ, later showed that the DE 
ratio was lower for late-responding tissues than that for early-responding tissues4. 
From equation 4 it follows that n1 fractions given with d1 Gy per fraction gives the 
same BED as the second fractionation scheme with n2 fractions given with d2 Gy 
per fraction by: 
 
            (5) 
  
The LQ model has been generally accepted both to model in vitro data and in vivo 
data and used extensively, especially for low to moderately high doses. However, 
for a dose per fraction on the order of 15 – 20 Gy as used in SBRT, the LQ model 
has been questioned53, 54. 
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3.5 OTHER MODELS 
Other models have been proposed and used to fit to cell survival data. A summary 
of the ability of different models to fit to cell survival data has been published55. A 
number of different models, including LQ, SHMT and USC, were used to fit to 
cell survival data for a number of cell lines irradiated to maximum fractional doses 
of 7 to 15 Gy. More recent models than LQ are now recommended for high 
fraction doses as used in SBRT55.  
 
Use of the LQ model has also been suggested for the high dose region with a very 
high DE ratio56 . At an infinitely high DE ratio, LQ turns into a pure exponential 
function, similar to the high dose part of the USC model. However, LQ with a very 
highDE ratio cannot make correct predictions in the low dose region.   
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4 EFFECT VERSUS SPATIAL DOSE DISTRIBUTION 
 
Treatment planning and delivery capabilities in radiation therapy have changed 
dramatically since the introduction of three-dimensional treatment planning 
systems (TPSs) and are continuing to change relatively rapidly due to the 
implementation of newer advanced technologies. Three-dimensional conformal 
radiation therapy (3DCRT) is now firmly in place as the standard of practice in 
clinics around the world. In intensity modulated radiotherapy (IMRT), the beam 
fluence is varied optimally to achieve the desired dose distribution that closely 
conforms to the prescription dose of the target volume and/or avoids specific 
sensitive normal structures. The increasing use of IMRT, delivered either with 
static beams or arc therapy, has focused attention on the need to better account for 
the intra- and inter-fraction spatial uncertainties in the dose delivery process 57.   
The continuous technological and methodological developments have improved 
spatial dose distributions, making possible the delivery of higher doses to target 
volumes for improved outcomes. Accordingly, the importance and understanding 
of the relationship between spatial distribution of the delivered dose to OAR and 
the probability of a specific side effect has become ever more complex. 
 
4.1 HOMOGENEOUS DOSE 
Historically, owing to technological limitations, dose distributions conformed less 
to the target volume and the complete volumes of OAR were relatively often 
irradiated, and often with a homogeneous dose distribution58.  In this situation the 
effect was considered to be a function only of the number of fractions and the dose 
per fraction as described in Chapter 3. Even today, part of the dose-response data 
that is available and used in the clinic is based on treatments that was given with a 
homogeneous dose distribution to the OAR. This applies especially to radiation-
induced injuries that appear long after the treatment.  
Also for the simplest situation, with a homogeneous dose to the OAR, considerable 
uncertainties in dose–response curves exist. The causes are due to uncertainties in 
the actual dose delivered as described later in Chapter 5, but primarily due to 
difficulties in defining and measuring clinically relevant end-points and the lack of 
follow-up data consistent with a well defined end-point as discussed in the 
Introduction.  
 
4.2 INHOMOGENEOUS DOSE  
The fact that normal tissues close to the tumor are nearly always non-uniformly 
irradiated in 3DCRT and especially in IMRT further complicates the use of any 
model to predict the response of an OAR. With the introduction of 3D dose 
planning in the beginning of the 1990s, dose-volume histograms (DVH) were also 
introduced as a way to condense data; however with the loss of the spatial 
information about the dose distribution within the organ. A DVH gives the 
percentage of a particular structure that receives a specified dose. They are often 
graphed as cumulative DVHs, showing the cumulative volume versus dose. Today, 
DVH data are generally used to correlate with incidence data for the generation of 
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4.3 NTCP MODELS 
Normal Tissue Complication Probability (NTCP) models, although complex, have 
the attractive feature of considering the complete dose distribution throughout the 
organ of interest. There are a number of NTCP-models62, of which many are based 
on three tissue-specific and endpoint-specific parameters in order  to predict the 
response to radiation. Usually one parameter, describes the dose at which a 50% 
probability of the response in question is predicted (D50), a second parameter 
describes the slope of the dose-response curve, and one third describes the volume 
dependence of the tissue in question. 
 
The Lyman-Kutcher-Burman model, LKB: 
This model uses the probit formula to describe the dose-response relationship, 
characterized by the parameters D50 and m (the slope of the response curve at 
D50)63-65. When considering non-uniform dose distributions, the differential DVH 
is converted to an equivalent uniform dose (EUD, equation 9). The parameter n 
determines the relative importance of different volume fractions. More explicit, n 
is a volume dependence parameter. NTCP is calculated by: 
 
 
 
                                                (8) 
 
where 
 
 
 
 
Di and Vi are respectively the dose to the corresponding volume of the ith bin of 
the differential DVH. 
 
 
The Logit+EUD model, LOGEUD: 
This model uses the logit formula coupled with the generalised-EUD reduction 
algorithm66 by equation 11. The logit formula describes the dose-response 
relationship for normal tissues through D50 and k (the slope of the response curve 
at D50): 
 
    (11) 
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where Di and Ȟi are, respectively, the dose to the corresponding relative volume 
of the ith bin of the differential DVH. 
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The Mean-Dose model, MD 
This model is derived from the LOGEUD model when the volume effect 
parameter (n) is equal to one 67. The DVH is thus reduced to the mean dose (MD) 
and NTCP is calculated through equation 13: 
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                              [13] 
 
The relative seriality model, RS 
This model is based on Poisson statistics and it accounts for the architecture of the 
organ through the parameter of relative seriality s61. The relative seriality is derived 
from the ratio of serial subunits to all subunits in the organ. For a heterogeneous 
dose distribution the complication probability is given by: 
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where M is the number of calculation subvolumes in the dose calculation volume, 
Di is the dose in the subvolume considered and ǻȞi=vi/V where vi is the volume of 
each subvolume in the DVH and V is the total volume of the organ. P(D) is the 
Poisson dose-response relationship: 
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where D50 is the uniform dose that causes 50% probability of injury and Ȗ is the 
slope of the response curve at D37. 
 
Several NTCP models and many DVH parameters may seemingly accurately 
describe the risk of RP for broad populations of patients. However, a statistically 
significant association or description of complication rates for populations of 
patients may not be the same thing as a good predictor of toxicity for an individual 
patient due to inherent differences in radiation sensitivity among patients. Many 
published studies on the incidence of RP are also limited at least in the following 
aspects: the number of toxicity-events is low with large statistical uncertainties as a 
consequence; data were mostly from patients treated with RT without the use of 
3DCRT, IMRT, stereotactic RT, or proton therapy. The conclusions of the studies 
might then be appropriate only for the study of specific populations. 
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5 UNCERTAINTIES IN PATIENT DOSES. 
 
Dose-response data in the literature contain considerable uncertainties31. The 
problems with quantifying responses in the lung are described in Chapter 1.5. This 
chapter concerns the problem with uncertainties in dose delivered to the patient 
where geometrical uncertainty is one part and uncertainties in dose calculation, 
dose delivery and conversion to biological equivalent dose is another part. The 
goal is to determine the “true dose” delivered to an individual patient over the 
complete course of the RT, for the generation of accurate dose-response data68. 
 
Spatial uncertainties 
In the RT process, one of the first steps is the definition of target and OAR 
volumes. Depending on the type of images used in this step, contrast resolution in 
the images will to a large extent determine the accuracy in the delineation, apart 
from the skill of the responsible physician. Spatial uncertainties about dose 
delivery are usually separated into two categories: variations in the positioning of 
the patient's bony anatomy with respect to the beam (setup errors), and variations 
in the position/shape/size of the target and OAR within the patient with respect to 
the bony structures (organ motion/deformation). Organ motion can be sizeable as a 
result of breathing, leading to significant increase in the volume of normal tissue 
irradiated. Target motions due to breathing may be accounted for both in the CT 
before dose planning and in the treatment by, respectively, 4D-CT and gating 
during the treatment. 
Multiple strategies are available for increasing the geometric precision of RT, 
including immobilization and setup aids for reducing random and systematic 
components of setup errors and organ motion alike. Alternatively, more complex 
strategies can be implemented based on additional information with the use of 
image guided radiotherapy (IGRT) acquired over the course during which 
corrections can be made off-line and on-line69. The strategies that are implemented 
in the clinic must include the required geometric precision for a given treatment, 
where 3DCRT have larger margins owing to respiratory motions compared to 
SBRT, during which breathing motion often is reduced by abdominal compression. 
 
Dose uncertainties 
Spatial uncertainties, both systematic and random (including breathing motions) 
will transform into uncertainties about dose. Today attempts are made to develop 
software in which dose is accumulated throughout the course of the treatment 
based on imaging during the treatment in order to determine the actual dose 
delivered68. However, this section will deals with uncertainties in dose calculation 
and in dosimetry for the static situation based on non-4D imaging.  
Much of dose-response data available and in clinical use today stems from the time 
when dose calculations were done with relatively simple pencil beam algorithms70. 
Regarding dose to lung tissue it may even be that correction for the lower density 
in lung was not performed71, 72. As an example of errors caused by simple pencil 
beam algorithms, we now know that they overestimate the dose to the lung tissues, 
located close to unit-density tissues73.  
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In the simple pencil beam algorithms, correction for tissues that deviate from water 
is performed only along a straight path, i.e., the pencils, but not laterally. In 
superposition-convolution algorithms, now in general use in TPS today also the 
change in lateral transport of secondary particles in non-water media is accounted 
for.  In that method, dose contributions from the primary and scattered radiation 
are calculated separately. For each point in a volume (voxel), the corresponding 
attenuation coefficient is determined from the CT data, and the primary radiation 
beam is attenuated accordingly. A kernel, representing the distribution of scatter 
from that point, is then applied to each voxel, weighted according to the amount of 
primary radiation that was attenuated at that point and with the scatter kernel 
scaled according to the mean density between the points of energy release and 
deposition. By summing doses from the primary radiation and scattered radiation 
arising from each voxel, a more accurate dose distribution is generated compared 
to simple pencil beam algorithms. In benchmarking of dose planning algorithms, 
Monte Carlo generated data for complex geometries like patient data is often used. 
Currently, dose planning algorithms based on Monte Carlo simulations are 
available, and are considered to be the most accurate algorithms, although 
advanced superposition-convolution algorithms are relatively close.  
 
Uncertainty about the dosimetry, i.e. the calibration of the monitor ion chamber of 
the treatment unit and/or changes in beam characteristics, such as beam flatness, 
are judged to be a minor source of error at present. More important is the effect of 
different fractionations used in the data gathered, for determination of dose-
response curves. Unfortunately this is far from always considered58.  
 
In summary, considerable uncertainty remains about dose data as well as incidence 
data that was used for determination of some of the dose-response relations in use 
today74. However, one could argue that dose-response data generated by a 
particular methodology has primarily clinical relevance in the same 
methodological context. An example would be lung-dose effects after RT of BC, 
always 2 Gy/fraction to the target volume, the use of a simple pencil beam 
algorithm for dose planning and no correction for fractionation. But with a view 
toward the future, this of course, is not creative for generation of improved dose-
response data and or for the development of RT. Suggestions and initiatives are 
taken to pool high-quality datasets from multiple institutions in order to improve 
the modelling74. 
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6 MATERIAL, METHODS AND RESULTS 
The effect of spatial and temporal dose distributions on radiation induced side 
effects in the lung were investigated, for both conventional RT for breast cancer 
and SBRT for lung cancer. 
 
6.1 CONVENTIONAL RT FOR OF BREAST CANCER (PAPERS I, II) 
Four hundred and seventy-five BC patients, referred to the Radiotherapy 
Department at Stockholm Söder Hospital (1994–1998) for adjuvant post-operative 
RT were prospectively followed for pulmonary complications 1, 4 and 7 months 
after the completion of RT. Prescribed doses were 46 Gy or 50 Gy in 2 Gy 
fractions. The frequencies of RP requiring corticosteriods at Södersjukhuset were 
found to be 10 % among patients treated with loco-regional RT including the IMN. 
The results also showed that irradiated lung volume was associated with RP and 
that the estimated risk increased if more than 30% of the ipsilateral lung volume 
received more than 20 Gy75. A subset of patients who were diagnosed with severe 
pulmonary complications needing cortisone treatment had a significant functional 
loss comparable to 15 years of normal ageing or the loss of 3/4 of a lung lobe 
compared to the patients who were asymptomatic when measured at 6 months after 
RT38.  
 
In paper I radiological changes in the lung tissue after RT for BC were quantified 
with CT in 121 of the patients included above. The association of radiological 
changes with spatial dose distribution and symptomatic RP was documented.  CT 
scans were performed at two levels through the lungs before RT and 4 months 
afterwards, one at a level of about 3 cm above the mamillary plane and one at an 
apical CT slice at the superior aspect of the clavicular head as shown in Figure 9. 
The change in mean density (Hounsfield number) was measured in three different 
regions (entire slice, anterior half and anterior third) for each of the two levels.  In 
Figure 10 typical density change after RT for loco-regional RT is shown. 
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In paper II, a cohort of 87 of the above 121 patients were further analyzed. 
Correlations between the incidence of short-term pulmonary complications and 
lung-dose/volume and fractionation parameters were documented. Data from 
dose–volume histograms of the complete ipsilateral lung and incidence data were 
fitted with four different NTCP models. Each bin of the dose-volume histograms 
was corrected for fractionation to 2 Gy per fraction using the LQ model with a Į/ȕ 
ratio of 3 Gy. The end-points considered in this study were: symptomatic (clinical) 
RP, X-ray assessed lung density changes and CT assessed lung density changes.  
Clinical pneumonitis was defined according to modified CTC-NCIC grades 0–2. 
Patients with of grade-1 or -2 pneumonitis were grouped together in the analysis 
and compared with asymptomatic patients.  Density changes on chest X-ray were 
scored according to a system originally suggested by Arriagada76 which divides the 
lung field into three regions: the apical-lateral, central-parahilar and basal-lateral. 
The highest density grades in each region were added together to form scores 
ranging from 0 to 9. Total scores of 1–3 were considered to represent slight 
radiological pneumonitis and scores of 4–9 moderate to severe.  
Density changes on chest CT were evaluated using two scan sets of the thorax: the 
first one was taken prior to RT for treatment planning purposes and the second 4 
months after the completion of RT. Each lung was divided into three regions and 
density changes were scored and grouped together in the same way as described 
above for the evaluation of chest X-ray changes. Also in this analysis no/slight RP 
was compared to moderate/ severe events.  
The four different NTCP models used were: the Lyman model with DVH reduced 
to the equivalent uniform dose (LEUD), the Logit model with DVH reduced to 
EUD (LOGEUD), the Mean Lung Dose (MLD) model and the Relative Seriality 
(RS) model. The data-fitting procedure was done using the maximum likelihood 
analysis, based on individual DVHs and binary incidence data (0 = no 
complication, 1 = complication).   
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Figure 12. Results for modelling with the LOGIT+EUD model. NTCP versus EUD is 
shown. The end-points were clinical RP (upper panel), incidence diagnosed by CT 
(middle panel) and X-ray assessed density changes (lower panel). 
 
 
Figure 12 shows the results of modelling for the LOGIT+EUD model. The 
incidence data in the figure (solid symbols) have been pooled and sorted into bins 
of 2 or 4 Gy. The solid line shows the results of modelling and the dotted lines the 
two-dimensional 68% confidence interval for the NTCP curve. All the studied 
NTCP models fit quite accurately the endpoints considered.  EUD or MLD were 
shown to be robust and simple parameters correlated with the risk of RP. This 
result is consistent with those from other studies in which MLD correlated with the 
incidence of RP, although there is a large range of dose used for different studies30. 
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The present study resulted in a D50 value significantly lower than many other 
studies, which might be explained by differences in the definition of the end-point. 
In this study only early pulmonary complications were evaluated. 
 
In a continued work to reduce RP in BC patients treated with loco-regional RT at 
Södersjukhuset, the use of dose-volume constraints significantly reduced post-RT 
radiological changes on chest X-ray77. Symptomatic pneumonitis was very rare in 
this study. Only one patient of 88 developed a moderate reaction. Mild reactions 
were detected in 6 patients. Furthermore, no relationship was found between 
symptomatic RP and radiological RP on chest X-ray or CT, but only one patient 
was diagnosed with RP, so no statistically relevant conclusion can be made. 
  
 
6.2 SBRT WITH HYPOFRACTIONATION (PAPERS III, IV, V) 
SBRT with hypofractionation of tumors in the lungs differs considerably from 
conventional RT for breast cancer with regards to both spatial and temporal dose 
distributions in the lungs, as described above. Although these two treatment 
methods represent extremes, investigations of both provides considerable insight 
into the radio response of lung tissue. In SBRT the questions to be analyzed are 
similar to those for BC when modelling complications, but an additional important 
question in SBRT is the analysis of uncertainties in dose due to the algorithm for 
dose computation in dose planning and of breathing motions during the 
treatment78.  
 
In paper III the accuracy of the calculated spatial dose distribution in SBRT for 
tumors in the lungs, including breathing motions were investigated. The accuracy 
of a number of dose planning algorithms in commercial systems (Eclipse, TMS-
HELAX and Pinnacle) were investigated by comparison with Monte-Carlo (MC) 
calculated dose distributions in a phantom for two different tumors, diameters of 2 
and 5 cm, located in lung equivalent material. The geometry of the phantom was 
cylindrical with a pentagonal cross section and with the tumor in the center, 
surrounded by lung. The geometries were simple enough to be accurately 
implemented in the MC code and in the TPSs but still amenable to study 
uncertainties stemming both from algorithms and motions. Five beams of 6 MV, 
were used to represent typical SBRT dose plans. Dose calculations were done with 
two simple pencil beam algorithms and two superposition-convolution algorithms 
in which the change in lateral transport of secondary particles in lung is accounted 
for. The impact of breathing motions on dose to target and to lung was also 
investigated by using MC simulations. In these, published patient data for 
breathing motion patterns were used including both longitudinal and transverse 
motions but simplified to a linear motion without the hysteresis seen in actual 
patient data79, 80. Longitudinal and lateral dose distributions were calculated as well 
as dose-volume histograms for target volumes, lung minus GTV and PTV minus 
GTV.  
 
The analysis showed that the dose in the central part of the gross tumor volume 
(GTV) is calculated for both tumor sizes with an accuracy of 2–3% with pencil 
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beam and superposition-convolution algorithms, compared to MC calculation, as 
shown in Figure 13 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Simulated dynamic case. Calculated longitudinal dose profiles for a 
simulated 2 cm tumor in lung tissue. Pencil beam algorithms, TMS and Eclipse, as 
well a superposition-convolution algorithm (CC) is compared to MC for both static 
and a dynamic case with a respiratory motion up to ±16 mm. Gray area represents the 
GTV and green square PTV. 
 
At the periphery of the GTV, the dose planning algorithms overestimate the dose 
up to 10%, whereas in the lung tissue between PTV and GTV pencil beam 
algorithms generally overestimate the dose and the superposition-convolution 
underestimates it. Furthermore, there are differences between the two pencil beam 
algorithms as well as between the two superposition-convolution algorithms. 
Two different respiratory motion patterns, representing different amplitudes, were 
included in the dose calculation with the MC. From the results of these calculations 
it was concluded that the dose to the GTV was considered relatively accurately 
estimated by the dose planning algorithms and the MC simulations for the static 
situation, as shown in Figure 13. On the other hand, the dose at the periphery of the 
GTV is overestimated, compared to the static case. A "narrowing" of the 
longitudinal dose profile of up to 20 mm (at about 90% dose level) is seen relative 
the static dose profile calculated with the pencil beam algorithms. An explanation 
for the relatively small impact on the dose to GTV, when breathing motions are 
included, is the inhomogeneous dose distribution in the PTV. The GTV is moving 
into higher and lower dose regions with the respiratory motion, which are partly 
compensating for each other. 
An important conclusion from this investigation is that failure to consider 
breathing motions in the dose calculation will have a smaller impact than the 
choice of dose planning algorithm when one estimates the dose that will actually 
be delivered. This result is, however, based on the use of a very inhomogeneous 
dose distribution within the PTV and cannot be applied for a homogeneous dose 
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distribution as used in conventional RT. Furthermore, the algorithm used must be 
reported together with dosimetric data in publications on follow-up data. 
 
In paper IV, the impact of fractionation correction with the LQ and USC models 
was investigated for the modelling of lung toxicity after SBRT for lung tumors. 
The toxicity data used were from 57 patients included in a phase II multicenter trial 
on SBRT for medically inoperable stage I NSCLC; of this group 10.5% were 
diagnosed with RP2+42. The prescribed dose to target was 22 Gy x 3 at the 
isocenter with 15 Gy per fraction at the periphery of the PTV.  The dose planning 
involved two simple pencil beam algorithms implemented in two different TPSs, 
TMS-Helax and Eclipse. The dose to the high dose regions, in the volume between 
PTV and CTV was overestimated according to results in paper III and the dose to 
the lung volume outside the PTV was underestimated (Figure 13). Attempts were 
made to find a simplified dose correction algorithm to correct for the lack of 
accuracy of pencil beam algorithms to be applied on DVH data retrospectively. 
Because these attempts were unsuccessful, original dose data were used in the 
NTCP modelling. To investigate the impact of fractionation correction two 
different models the LQ model81 and the USC model53, 54  were applied to dose 
data for each individual DVH for lung minus GTV. The NTCP-modelling was 
done using the Lyman-Kutcher-Burman (LKB) model63, 65.  
 
Parameter values of D0 and      in the USC model were determined from estimated 
values of D and dT. In the LQ model a DE ratio of 3 Gy was used. In the fitting 
procedure, parameter values of n in the LKB model were determined for a range of 
values of m and D50, so the mean NTCP for the 57 patients was 10.5%, in 
accordance with the incidence.   
The result of the NTCP modelling indicates a more serial like response of the lung 
with the USC correction for fractionation, as compared to that with LQ correction. 
As a consequence, low dose volumes were found to contribute less and high dose 
volumes more to the NTCP when using the USC model compared to the LQ 
model. Still, additional clinical data are needed in order to reach more reliable 
conclusions. 
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Figure 15 Calculated isoeffect curves, normalized to 22 Gy x 3 for tumor and normal 
tissues using LQ or USC for fractionation correction. The number of fraction increases to 
the right on the dose/fraction axis. 
 
At a dose per fraction below about 6 Gy (case 2.1) the LQ and USC models predict 
the same fractionation sensitivity (slope) as shown in Figure 15. At a high dose per 
fraction, above about 15 Gy, the USC model predicts much lower fractionation 
sensitivity, compared to the LQ model. Further the therapeutic window was shown 
to increase with an increasing number of fractions in SBRT, compared to the 
commonly used three fractions. Both the LQ and USC models predicted this 
outcome, but generally a clearly greater gain is predicted with the USC model. 
Specifically, the USC model predicts a higher sensitivity for fractionation than the 
LQ model (for iso effective tumor doses) if the OAR receives less than the dose 
given to the GTV. The greater gain predicted by the USC model applied to both 
cases, denoted as 2.2 and 2.3 in Figure 15.  
 
The results from paper V have had an impact on clinical SBRT at Karolinska 
University Hospital in the sense that large tumors and centrally located lung 
tumors with adjacent sensitive structures are generally treated now with 8 to 10 
fractions. Furthermore, a phase II multicenter trial on patients with lung tumors 
located less than 1 cm from the main/lobar bronchi has been initiated from 
Karolinska. Here, 8 fractions with 7 Gy/fraction are given at the periphery of the 
PTV.  Other centres have also adopted a less extreme hypo fractionation than 3 for 
lung tumors at a central location. At VUMC in Amsterdam 8 x 7.5 Gy have been 
used and preliminary results on local control are similar to those from treating with 
5 x 12 Gy or 3 x 20 Gy, with generally very low toxicity82. This preliminary 
clinical result indicates very low fractionation sensitivity at very high 
doses/fraction in correspondence to the results in Figure 12. 
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7 CONCLUSION AND FUTURE POSSIBILITIES 
In this thesis radiation induced side effects in lung tissue after radiotherapy in the 
thorax region were studied. The overall aim was to investigate how radiation 
induced side-effects correlates with and can be modelled in terms of the spatial and 
temporal distributions of the dose delivery in conventional RT for BC and 
hypofractionated SBRT for lung cancer. 
The results showed, first, that short-term lung density changes and symptomatic 
RP were associated with RT techniques after RT for BC. The apical part of the 
lung appeared to be less radiation sensitive than the central part. Furthermore, RP 
grade I after RT for BC was accurately modelled with NTCP models and EUD and 
MLD are simple parameters that correlate with the risk of RP. 
 
Second, for SBRT of lung tumors, the accuracy in dose to the GTV is relatively 
insensitive with respect to the algorithm used for dose planning, even considering 
breathing motions at dose delivery. However, at the periphery of the GTV and 
especially in the lung tissue outside but close to the GTV, the dose is considerably 
overestimated with the simplest algorithms. Improved algorithms that take into 
account the change in lateral transport of secondary particles is, however, relatively 
accurate in the estimation of dose to the lung. 
From incidence data of RP grade 2 or more after SBRT of lung tumors, parameter 
values in the LKB NTCP model were determined for the lung using both the LQ 
and USC models for fractionation correction. The parameter values so determined 
were used to investigate the impact on the therapeutic window with increasing 
numbers of fractions in SBRT for lung tumors. When fractionation correction with 
the LQ and USC models were compared a larger gain was predicted by the USC 
model by increasing the number of fractions from 3 to about 10. At a very high 
dose per fraction the sensitivity for fractionation is considerably lower as predicted 
by the USC model compared to that for the LQ model. 
 
To use dose/volume constraints that are available in the literature, knowledge of 
underlying data is important. Uncertainties in clinical response data stem partly 
from the difficulty of specifying end-points that are straightforward to quantify. 
For the lungs, the response to radiation is to some extent a continuous effect with a 
gradual change in severity. In general, there is a lack of accurate data for the more 
severe end-points. 
To safely use dose/volume constraints today only the context in which they were 
created may be relevant. However, this would restrict the use of dose-response 
relations in the generation of hypotheses for developments in RT. Thus, consistent 
modelling of dose/volume parameters in the determination of dose-response 
relations will be more fruitful for the future. 
The causes of some uncertainties in dose delivery to the patients are set-up errors 
and organ motions, which can make the delivered dose unreliable compared to the 
calculated dose to an organ. Uncertainties in static dose calculations are today a 
minor problem because relatively accurate dose planning algorithms based on 
Monte Carlo simulations are now available, as are the superposition-convolution 
algorithms now in use. Still, dose calculation that takes into account organ motion 
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and deformations must be implemented if uncertainties in calculated dose to OAR 
are to be reduced. Uncertainties in dose-response relations are highly dependent of 
how the correction for fractionation is done in the data gathered, especially for high 
doses per fraction. 
To assure the reliable prediction of side-effects, more clinical studies are needed 
and the uncertainties in both the definition of clinical findings and in dose delivery 
have to be addressed and reduced. 
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